Fungus-Derived pill aims to rebuild cancer Patients' weakened immunity
NCT ID NCT07258160
Summary
This study is testing if a pill called PRaG-1 (cordycepin) can help restore a specific type of weakened immune cell in cancer survivors. It will involve about 127 adults who are free of solid tumors but have low CD8+ T-cell counts after finishing chemotherapy or radiation. Participants will take the pill for two weeks, and those who respond well will be randomly assigned to either continue it or switch to a placebo to see if the benefit lasts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.